Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors Full Text
Biologics: targets & therapy,
Brown–Glaberman U et al. – The data presented highlight the differences associated with intravenous bisphosphonate and denosumab use as well as confirm the essential role bone–modifying agents play in maintaining the quality of life for patients with bone metastases.



